edistride
astrazeneca ab - dapagliflozin propāndiols monohidrāts - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - cukura diabēts - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. papildus citām zālēm, lai ārstētu 2. tipa cukura diabētu. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 un 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.
forxiga
astrazeneca ab - dapagliflozin propāndiols monohidrāts - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - cukura diabēts - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. papildus citām zālēm, lai ārstētu 2. tipa cukura diabētu. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 un 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.
dapagliflozin viatris
viatris limited - dapagliflozīns - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - cukura diabēts - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 un 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.
daglin 5 mg apvalkotās tabletes
zaklady farmaceutyczne polpharma s.a., poland - dapagliflozīns - apvalkotā tablete - 5 mg
daglin 10 mg apvalkotās tabletes
zaklady farmaceutyczne polpharma s.a., poland - dapagliflozīns - apvalkotā tablete - 10 mg
dapagliflozin polpharma 5 mg apvalkotās tabletes
zaklady farmaceutyczne polpharma s.a., poland - dapagliflozīns - apvalkotā tablete - 5 mg
dapagliflozin polpharma 10 mg apvalkotās tabletes
zaklady farmaceutyczne polpharma s.a., poland - dapagliflozīns - apvalkotā tablete - 10 mg
dagrafors 5 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - dapagliflozīns - apvalkotā tablete - 5 mg
dagrafors 10 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - dapagliflozīns - apvalkotā tablete - 10 mg